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Abstract
Randomized trials, and even observational studies used for causal inference, are
rarely representative of the populations in which the results will be used to inform
clinical decision making. In order to account for differences between populations,
we may consider standardizing results to a target population. In this paper, we dis-
cuss different approaches for reasoning about which covariates must be standardized
over, and different approaches for computing the standardized causal effect in the
target population. We compare and contrast these approaches, with an emphasis
on evaluating whether the necessary assumptions underlying each method can be
expected to hold in standard clinical and pharmacoepidemiological settings. We
conclude that the choice must be informed by expert beliefs about which assump-
tions are most likely to be approximately true in the specific scientific context.
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1. BACKGROUND
The participants in randomized trials (and even in observational studies) are often not
representative of the populations faced by clinical decision makers. Several statistical
methods have been proposed to standardize estimates of a causal effect over a set of base-
line covariates to account for differences between the study population and the target
population. However, less attention has been given to how an investigator should reason
about which covariates need to be standardized for. The choice of variables is important
not only for the standardization procedure, but also for determining which personal char-
acteristics of the participants must be considered when reasoning qualitatively about how
representative a study is. In this paper, we discuss different ways to select such covariates,
and show that this problem is closely related to how one chooses to operationalize effect
homogeneity between populations.
Epidemiologists and clinical scientists have traditionally defined effect homogeneity in
terms of effect measures that compare the average outcome under an active treatment
with the average outcome under an alternative. For example, one may consider effect
homogeneity as absence of effect modification on the risk ratio (RR), the risk difference
(RD) or the odds ratio (OR) scale. These definitions of effect homogeneity are associated
with several established conceptual and practical shortcomings, including lack of biological
interpretation, baseline risk dependence, zero bounds, prediction outside the range of valid
probabilities, non-collapsibility and asymmetry[1].
There have also been several recent methodological developments in defining effect
homogeneity based on counterfactual distributions rather than specific measures of ef-
fect. These approaches consider the outcome under the active treatment separately from
the outcome under the control condition. VanderWeele described this approach as “ef-
fect modification in distribution” [2], to contrast with the standard approach, which was
termed “effect modification in measure”. Although methods based on assuming condi-
tional homogeneity of the distribution of a counterfactual variable are mathematically
elegant and avoid most of the limitations of defining homogeneity with respect to ef-
fect measures, they require strong assumptions which go well beyond the conditions that
clinical scientists have traditionally considered necessary for generalizability.
The paper is organized as follows. First, we consider approaches to variable selection
that are based on conditional homogeneity of standard effect measures such as RR and
RD. We then describe the recently introduced counterfactual outcome state transition
(COST) parameters[1], and show how this framework can be used to overcome some of
the shortcomings of traditional effect measures. Finally, we review approaches to variable
selection based on conditional homogeneity of individual counterfactual distributions,
with a particular emphasis on methods based on inverse probability weighted estimators,
and methods based on causal diagrams for research transportability. As we introduce
each approach, we repeatedly refer to two tables throughout the text: Table 1 shows an
overview of different ways an investigator can operationalize effect homogeneity; Table
2
2 shows five different approaches to standardization which rely on different homogeneity
conditions.
For all examples, we will consider the effect of a binary treatment A (for example,
a pharmaceutical; 1 = treated, 0 = not treated) on a binary outcome Y (for example,
a side effect; 1 = occurred, 0 = did not occur). We will let V denote a set of baseline
covariates which are potential effect modifiers (for example: gender, nationality, etc).
We will consider two separate populations: The study population (P = s), and the
target population (P = t). Counterfactuals will be denoted using superscripts. We
will focus primarily on binary outcomes, but note that most discussions (except that
of COST parameters) extends readily to continuous and time-to-event outcomes. We
consider several measures of causal effect including the RD, the RR, the survival ratio
(SR) (which can be understood as the RR where the coding of the outcome variable is
reversed), and the OR. These effect measures may be defined in a specific population or
subgroup, which we denote using subscript as needed. For instance, RDt is the RD in
population t.
We will consider two closely related classes of problems: In the first class of problems,
which arises commonly in the context of external validity and research generalization,
we will assume that we have evidence for the causal effect of the treatment in a study
population and that we wish to predict the effect of introducing the treatment in the target
population, in which we only have confounded observational data (“transportability” or
“generalizability”). In the second class of problems, which arises commonly in meta-
analysis and model specification, we have data on the causal effect of the pharmaceutical
from two or more populations, which we wish to summarize under a plausible homogeneity
assumption. Unless stated otherwise, we will consider membership in the study population
to be defined at baseline; and focus on issues that arise due to non-random selection into
the study. We note that while it is certainly possible that there is selection out of the
study post-baseline, this is better considered as a form of selection bias [3, 4] related to
internal as opposed to external validity.
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Table 1: Definitions of Conditional Effect Homogeneity
Definition
Effect Homogeneity in Measure
On the risk difference scale RDs,v = RDt,v
On the risk ratio scale RRs,v = RRt,v
On the survival ratio scale SRs,v = SRt,v
On the odds ratio scale ORs,v = ORt,v
Homogeneity of COST Parameters
For introducing treatment Y a=1 ⊥ P |Y a=0, V
For removing treatment Y a=0 ⊥ P |Y a=1, V
Effect Homogeneity in Distribution
S-ignorability Y a ⊥ P |V (∀a)
S-admissibility Y a ⊥ P a|V a (∀a)
4
Table 2: Five Approaches to Effect Transportation
Interpretation of result Required Covariates Validity Conditions
RRt =∑
v
RRs,v × Pr(V = v|Y
a=0
= 1, P = t)
Effect measure in target
population
A sufficient set of effect
measure modifiers
Conditional effect homogeneity in
measure. The weights shown in this
example (Pr(V = v|Y a=0 = 1, P =
t)) are specific to the risk ratio; sim-
ilar weights exist for other collapsi-
ble effect measures but not for non-
collapsible effect measures.
Pr(Y
a=1
= 1|P = t) =∑
v
[
Pr(Y
a=0
= 1|P = t, V = v)× RRs,v × Pr(V = v|P = t)
]
Average outcome under
treatment in target popula-
tion
A sufficient set of effect
measure modifiers
Conditional effect homogeneity in
measure
Pr(Y
a
= 1|P = t) =∑
v
[
Pr(Y
a
= 1|V = v, P = s) × Pr(V = v|P = t)
]
Average outcome under
treatment (or under no
treatment) in target popu-
lation
Variables sufficient to block
all paths between P and Y
Conditional effect homogeneity in
distribution
Pr(Y
a
= 1) =
E
[
Y × I(P = s, A = a)
Pr(A = a|V = vi, P = s)× Pr(P = s|V = vi)
]
Average outcome under
treatment (or under no
treatment) in population
from which the (biased)
sample was taken
Variables sufficient to block
all paths between P and Y
Conditional effect homogeneity in
distribution
Pr(Y
a
= 1|P 6= s) =
E
[
Y × I(P = s, A = a)
Pr(A = a|V = vi, P = s) ×
Pr(P =s|V =vi)
1−Pr(P =s|V =vi)
]
Average outcome under
treatment (or under no
treatment) in those who
were eligible to be selected
for the study, but weren’t
Variables sufficient to block
all paths between P and Y
Conditional effect homogeneity in
distribution
Note that in approaches 1 through 3, the identifying expressions for the effect in the target population are written in terms of counterfactual variables in order to focus on
the part of the analysis that is made necessary in order to account for heterogeneity between populations. In practice it will be necessary to find an identifying expression
that is written terms of observable quantities, which will require either marginal or conditional exchangeability ((Y a ⊥ A|P = s or Y a ⊥ A|P = s, V for ∀a) in the study
population. In approaches 4 and 5, the identifying expressions are written in terms of observable quantities; these expression rely upon conditional exchangeability for their
derivation. For simplicity of notation, we are here assuming that the same set of variables is sufficient to account both for confounding in the study population and for
differences between the populations. Note also that we do not in general assume that P is binary. In the special situation where P is binary (such that all members of a
well defined source population belong either to the study population or the target population), approach 5 estimates the effect in the same subgroup as approach 3.
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2. EFFECT HOMOGENEITY IN MEASURE
Effect homogeneity in measure occurs whenever the effect in one population (or subgroup)
is equal to the effect in another population (or subgroup) in terms of a particular effect
measure, such as the RD or the RR. For example, if the RD in the study population
(i.e. RDs) is equal to RD in the target population (i.e. RDt) we say that there is
effect homogeneity on the RD scale. If this condition holds within levels of a set of
measured covariates V we say that there is conditional effect homogeneity on that scale,
and that V is a sufficient set of effect measure modifiers for the transportation from the
study population to the target population. While effect homogeneity in measure could
in principle occur between strata of V , we will in this manuscript primarily focus on
homogeneity that occurs between populations, conditional on V , while allowing the effect
measure to vary between strata of V .
The overall idea behind approaches based on effect homogeneity in measure is to iden-
tify a set of measured covariates such that, within levels of the covariates, the magnitude
of the effect (when measured on that particular scale) is equal between the populations.
To illustrate, it is possible that the RR for adverse effects of Codeine differs between
Norway and Japan because the two countries have different distributions of variants of
CYP2D6 [5], a gene associated with drug metabolism, but that on average, the RR asso-
ciated with the use of the drug is equal between Norwegians and Japanese who have the
same variant of the gene. If that is the case, then we have effect measure homogeneity
conditional on CYP2D6 variant, and CYP2D6 is a sufficient set of effect modifiers on the
RR scale. Of note, a sufficient set of effect measure modifiers may not exist among the
measured covariates.
Many commonly used methods in epidemiology rely on assumptions that are equivalent
to conditional effect homogeneity in measure. For example, the Mantel-Haenszel estimator
only has a clear population-level interpretation if the conditional OR is equal between
all strata of the covariates [6] (i.e if there is effect homogeneity in measure between
strata). Epidemiologists also often rely on effect homogeneity in measure when they
omit interaction terms from regression models. For example, the logistic regression model
logit Pr(Y = 1|A,P, V ) = β0 + β1A+ β2P + β4V
by omitting a product term β3 ×A× P , encodes the assumption that the OR of A on Y
in the group P = s is equal to the OR in P = t, conditional on V = v, or in other words,
that there is conditional effect homogeneity on the OR scale.
Another example of a method that relies on conditional effect homogeneity in measure,
this time in the setting of generalizability, occurs when an investigator attempts to account
for heterogeneity between populations by standardizing an effect measure over a set of
covariates V . The first two formulas in table 2 can be used to standardize estimates of a
causal effect to a target population, if one has measured a sufficient set of effect modifiers.
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Approach one, which is a weighted average of the effect measure, is valid for collapsible
effect measures [7], whereas approach two, which is a weighted average of the predicted
stratum-specific average outcome under treatment, is valid for any effect measure.
A large literature exists on statistical tests for detecting and quantifying any effect
heterogeneity in measure. Examples of this include Cochran’s Q test [8] and the I2
statistic [9]. While homogeneity of an effect measure is to some extent an empirical
question [10, 11, 12], convincing arguments for stability of the effect measure outside
of the observed data will often require additional, explicit assumptions about the data
generating mechanism. Few examples of such data generating mechanisms exist in the
published literature.
2.1 COST parameters
COST parameters are a new class of effect parameters that were proposed in order to
formalize a counterfactual causal model that may result in effect homogeneity in terms of
standard observable measures of effect. The COST parameters for introducing treatment
are defined as follows:
G = Pr(Y a=1 = 1 | Y a=0 = 1)
H = Pr(Y a=1 = 0 | Y a=0 = 0)
The COST parameters can be understood as the proportion of cases and non-cases
that would not have had the opposite outcome if their exposure status had been altered.
In other words, these are the probabilities that the outcome does not “switch” in response
to treatment (see Figure 1). In Huitfeldt et al [1], it was shown that if certain cofactors
that determine treatment effect have equal prevalence between two groups, and if the
interaction between these cofactors and treatment A operates according to certain sim-
ple biological principles, then the COST parameters for introducing treatment are equal
between populations, which can mathematically be written as Y a=1 ⊥ P |Y a=0. If the
cofactors instead interact with treatment according to a different biological mechanism,
this would instead result in homogeneity of COST parameters for removing treatment
(Y a=0 ⊥ P |Y a=1).
Thus, by using the condition Y a=1 ⊥ P |Y a=0 to operationalize effect homogeneity,
we reframe homogeneity of the “magnitude of effect” as a matter of equal distribution of
certain cofactors. If there exists predictors of those cofactor which differ between groups,
such effect equality may hold within levels of those covariates V , in which case, there is
conditional equality of the effect of introducing (or removing) treatment. Conditioning
on V is then seen as an attempt to account for those variables that are predictors of the
prevalence of the potentially unmeasured background cofactors which determine whether
an individual “switches outcome” in response to treatment.
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Alive if untreated
Dead if untreated
Alive if treated
Dead if treated
H
1−
H
1−
G
G
Figure 1: Counterfactual outcome state transition parameters associated with introduc-
tion of treatment. 1-G is the probability that someone who would otherwise die survives if
treated. 1-H is the probability that someone who would otherwise survive dies if treated.
An applied investigator reasoning about covariate choice using the COST parameter
framework may consider many of the same aspects as would be considered for other effect
measures, but with the added advantage that the line of reasoning is specific to the relevant
effect measure. For example, suppose we are interested in generalizing findings about the
adverse effects of Codeine. The goal is to account for all cofactors that determine whether
a patient will respond to treatment, either by conditioning on those cofactors directly, or
by finding observable markers for their prevalence. For example, if the CYP2D6 variant
partly determines whether patients respond to Codeine, we could either condition on the
gene, or condition on ethnicity as a marker for its prevalence. Further, pre-study drug
use may be an observable marker for the prevalence of susceptibility, due to depletion of
susceptibles [13]. We will therefore measure and control for ethnicity and pre-study drug
use, as well as any other covariates that are relevant according to similar criteria.
COST parameters are generally not identified from the data without strong mono-
tonicity assumptions. If the treatment has positive monotonic effect (meaning that the
treatment does not prevent anyone from having the outcome), and if the COST parameters
G and H are equal between the study population and the target population conditional on
covariates V , there will be homogeneity on the SR scale for exposures which increase the
incidence of the outcome (SR becomes equivalent to H, whereas G is trivially 1). Anal-
ogous discussion applies when considering a situation in which the treatment of interest
is negatively monotonic (protective), in which case RR becomes equivalent to G, and H
is trivially 1. If treatment has monotonic effects, the COST parameters can therefore be
used as a “bridge” between the biological knowledge on the one side, and homogeneity
of observable measures of effects on the other side, thereby allowing the investigator to
standardize effect measure from a study to a target population using either approach 1
or approach 2 from Table 2. The necessary weights are discussed elsewhere [7]. The bias
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which is associated with the use of COST parameters in the presence of non-monotonicity
is small either if non-monotonicity is negligible, or if the baseline risks are similar between
the target population and the study population. Conditioning on additional covariates
will generally result in more similar baseline risks between populations, which means that
including additional covariates can sometimes reduce the remaining bias associated with
non-monotonicity, even if the additional covariates are not associated with cofactors that
determine outcome switching. If non-monotonicity is not negligible, the bias associated
with COST parameters may be substantial, and other analytic methods should be used.
The COST parameter approach often results in a recommendation to consider effect
homogeneity in terms of the RR scale for exposures that reduce incidence, and in terms
of the SR scale for exposures that increase the incidence, while keeping the coding of
the exposure such that the “natural state” of exposure has value 0 and the intervention
has value 1. Variations of this suggestion have arisen independently a number of times
in the previous literature [14, 15, 16, 17]. This approach is also consistent with the
Cochrane Handbook [18], which states that ”When the study aims to reduce the incidence
of an adverse outcome there is empirical evidence that risk ratios of the adverse outcome
are more consistent than risk ratios of the non-event” (the handbook does not take a
position on what effect measure to use when the study attempts to estimate the increase
in incidence of an adverse outcome). When the disease is rare, this approach is closely
approximated by the earlier suggestion to consider “relative benefits and absolute harms”
of interventions [19].
Finally, we note an important limitation of COST parameters, which is that they
have so far only been defined for binary outcomes. Extensions to continuous outcomes
and time-to-event have not yet been established.
3. EFFECT HOMOGENEITY IN DISTRIBUTION
An alternative approach is to operationalize effect homogeneity in terms of the individ-
ual counterfactual distributions under treatment and no treatment. Effect homogeneity
in distribution holds whenever the following two conditions hold simultaneously: (1) If
everyone in both populations were untreated, you would observe the same distribution
of outcomes in the two populations (Y a=0 ⊥ P ) and (2) if everyone in both populations
were treated, you would observe the same distribution of outcomes in the two popula-
tions (Y a=1 ⊥ P ). This condition was referred to as ”S-ignorability” by Bareinboim and
Pearl, and as ”exchangeability between populations” by Lesko et al [20]. VanderWeele [2]
showed that effect homogeneity in distribution implies homogeneity of all standard effect
measures; effect homogeneity in distribution is therefore a stronger assumption than effect
homogeneity in measure on standard scales.
In the previous section, we discussed the logistic regression model
logit Pr(Y = 1|A,P, V ) = β0 + β1A + β2P + β4V
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which omits the product term β3 × A × P , and showed that this model is justified
under conditional effect homogeneity in measure on the OR scale. We note that this model
could also be justified under conditional effect homogeneity in distribution. However, this
modeling approach has an immediate implication: If conditional effect homogeneity in
distribution holds and the effect of A on Y is unconfounded conditional on V and P ,
then β2 must be equal to zero (see Appendix 1). This makes the model subject to an
empirical test: if e.g. the Wald test rejects β2 =0, the model is misspecified. While
we do not recommend this as a test of the homogeneity assumption, we believe this
example illustrates that effect homogeneity in distribution is a very strong concept, and
that investigators often have to rely on a weaker form of effect homogeneity.
As with effect homogeneity in measure, effect homogeneity in distribution may hold
within levels of a set of covariates V . If effect homogeneity in distribution holds conditional
on V , one can use a third standardization formula (approach 3 in Table 2), based on
separately standardizing the conditional risk under treatment and the conditional risk
under no treatment from the study population, to the distribution of V in the target
population. Murray et al [21] shows how such standardization relates to agent-based
models, and shows how this approach may lead to biased transportability estimates in the
presence of unmeasured covariates whose distributions differ between the study population
and the target population.
Conditional effect homogeneity in distribution will often be implausible in realistic
randomized and observational studies. Specifically, whereas approaches that are based on
conditional effect homogeneity in measure aim only to control for those covariates that are
associated with the magnitude of the effect, methods that rely on conditional effect homo-
geneity in distribution are valid only if they account for every cause of the outcome that
differs between the study population and the target population. This may occasionally
be a reasonable assumption if the imbalance in covariates arises due to a fully understood
biased sampling mechanism, for example, if the investigators enroll participants from an
enumerated population with a different pre-specified selection probability for different
groups defined by measured baseline covariates, but outside of such stylized examples it
is more challenging to see good justifications for the required modelling assumptions.
We note that approaches based upon effect homogeneity in distribution do not make
use of possible information contained in the relationship between what happens if the
pharmaceutical is taken, and what happens if the pharmaceutical is not taken. To il-
lustrate, consider a situation where we have conducted a randomized controlled trial on
the effect of homeopathy vs no treatment on the incidence of cardiovascular disease, and
concluded that the effect in the study population is null. Suppose we are interested in
predicting the effect in a different target population, but we believe there may be un-
measured causes of cardiovascular disease that differ between the study population and
the target population. In such situations, if we operationalize effect homogeneity using
a notion of effect homogeneity in distribution, we are likely forced to conclude that we
are unable to make predictions for the target population. In contrast, investigators using
an approach based on effect homogeneity in measure could potentially be able to clar-
ify plausible conditions under which the null findings can be extrapolated to the target
population.
3.1 Weighted estimators for generalizability and transportability
One particular implementation of generalization based on effect homogeneity in distri-
bution originated with work by Stuart and Cole [22, 23]. These methods extend inverse
probability based estimators [24], which play a key role in previous work on causal mod-
elling [25, 26] to the setting of external validity. The validity conditions of these methods
are equal to those of standardization based methods discussed above.
Users of these methods often distinguish between “transportability” (where the ana-
lytic goal is to generalize the findings to a target population that does not include those in
the study population, i.e. a target population that looks like those who were not sampled
in the study), and “generalizability” (where the target population includes those in the
study population). The methods used for each objective differs in that inverse probabil-
ity of selection weights [20] (approach 4 in table 2) are used for generalizability, whereas
inverse odds of selection weights[27] (approach 5 in table 2) are used for transportability.
Stated slightly differently, the choice between weights based on inverse odds of selection
and weights based on inverse probability of selection is determined by whether the target
population is similar to the entire source population from which the study participants
were selected (conditional on baseline covariates), or similar to the subset of the source
population that was not selected for the study (conditional on baseline covariates). We
believe the first type of target population is more common; in such settings, inverse
probability of selection weights should be used. Inverse odds weights may be appropriate if
the study participants are sampled for a pilot study to determine whether the intervention
will be implemented in those who were eligible to be selected, but weren’t.
Inverse probability weighted methods have been applied to generalize the results of
trials on the effect of HIV medication [28] and treatments for substance use disorder [29].
Lesko et al provided a full description of how these methods can be used in practice [20].
Buchanan et al [30] provided results about the statistical properties of inverse probabil-
ity weighted estimators for external validity. Dahabreh et al [31] discussed estimators
based on augmented inverse probability weights; these estimators are doubly robust to
misspecification errors in the statistical models. Nguyen et al [32] showed how to conduct
sensitivity analyses on deviations from conditional effect homogeneity. Breskin et al [33]
provided results on bounds, i.e. intervals that show how wrong the point estimates can
be in either direction if the assumption of conditional effect homogeneity in distribution
is not fully met, in the presence and/or absence of confounding. If one suspects both
confounding and lack of effect homogeneity in distribution, these bounds can be used to
reason about target validity [34], that is, how much bias there may be in the estimates for
the target population as a result of deviations both from internal and external validity.
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U A Y
V P
Figure 2: In this selection diagram, there is an unmeasured common cause of A and
Y reflecting confounding in the target population. Note that both P and V are pre-
treatment variables in this diagram. The causal findings from the study population may
be transported to the target population if we have measured sufficient covariates V to
block all paths between the selection node P , and the outcome Y . We have chosen to
represent the selection node with an octagon.
3.2 Selection Diagrams
One example of a class of data generating mechanisms that guarantee effect homogeneity
in distribution (and therefore also effect homogeneity in measure for all standard effect
measures) was provided by Bareinboim and Pearl [35, 36, 37, 38], based on causal diagrams
[39]. These diagrams are, to our knowledge, the only published formal framework for
reasoning about which variables to adjust for when using approaches based on effect
homogeneity in distribution. In particular, they use a generalization of effect homogeneity
in distribution that allows the populations that the counterfactual distributions are equal
between, and the covariates that are adjusted for, to be downstream consequences of
treatment.
A selection diagram is constructed as follows: First, the investigator must provide a
causal directed acyclic graph (DAG) that is valid both for the study population and for
the target population. For this to be possible, the variables must be in the same temporal
order between the two populations. If that requirement is met, a DAG which is valid for
both populations can be constructed by including every node and edge from the causal
DAG in each population. After a shared causal DAG has been constructed, one must
also add (1) a selection variable node P , (2) all causes of the outcome whose distributions
differ between the populations, and (3) all paths between P and Y that one is not able to
rule out based on the temporal structure or expert knowledge. An example of a selection
diagram is shown in Figure 2.
Once a selection diagram has been constructed, one can check for transportability of
the results by determining whether Y is d-separated from P , given some set of measured
covariates V , in a manipulated graph where all arrows going into A have been deleted. If
such d-separation holds in the manipulated selection diagram, there will exist a transport
formula which identifies the causal effect in the target population based on a combina-
tion of observed quantities in the study population and observed quantities in the target
population. If V consists only of baseline covariates, then the transport formula is equal
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to the standardization formula discussed in the previous section.
Note that the independence relation that is queried by this d-separation approach can
be written algebraically as
Y a ⊥ P a|V a ∀a
which Bareinboim and Pearl referred to as “S-admissibility”. When P and V are pre-
treatment variables, P a = P and V a = V so the independence relation can be simplified
as
Y a ⊥ P |V ∀a
(or “S-ignorability”). This simplified version is identical to the previously discussed op-
erationalization of conditional effect homogeneity in distribution, which illustrates the
equivalence between the graphical approach and approaches based on standardization or
inverse probability weights when V and P are pre-treatment.
Thus, while the graphical approach and the inverse probability weighted approach
will result in very similar analyses if P and V are pre-treatment, the graphical model
allows a potentially useful generalization to settings where it is necessary to adjust for
post-baseline covariates. In practice, we are not aware of any published examples where
a convincing argument was made that a causal effect is transportable only by measuring
and adjusting for covariates that were causally affected by treatment.
4. CONCLUSIONS
Causal effects may differ between populations, and investigators will often have to stan-
dardize their estimates over a set of effect modifiers in order to make the results applicable
to clinically relevant populations. Before it is possible to begin reasoning about which
covariates must be standardized over, it is necessary to provide a definition of effect ho-
mogeneity. Several different approaches have been proposed.
If effect homogeneity is to be operationalized in terms of stability of a measures of
effect, the analytic objective is to account for all those covariates that are associated
with the magnitude of the effect on the chosen scale. COST parameters have been de-
veloped to formalize conditions that result in homogeneity of observable effect measures.
This approach requires that the investigators have accounted for all variables that predict
treatment response, that only baseline covariates are necessary for this purpose, and that
the effects of treatment are monotonic. When these conditions are met, using COST
parameters allows investigators to retain much of the underlying intuition behind tradi-
tional approaches to effect modification. Future work may be necessary to develop new
classes of causal models that result in homogeneity of other effect measures, including
effect measures relevant to time-to-event data.
If instead effect homogeneity is to be operationalized in terms of conditional homogene-
ity of the distributions of counterfactual variables (such as in methods based on inverse
probability weights and selection diagrams), the analytic objective shifts to accounting for
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all covariates that are associated with the counterfactual outcome and whose distribution
differs between populations. This will generally require a much larger set of covariates.
Controlling for all the necessary covariates will sometimes be feasible in situations where
the goal is to recover the estimates for the full source population in the presence of a fully
understood biased selection mechanism, but may be less realistic in other settings. If the
required conditions are met, methods based on effect homogeneity in distribution have
considerable advantages, as they do not rely on parametric assumptions or monotonicity
conditions.
All approaches have considerable limitations, and the choice between them will gener-
ally depend on expert beliefs about which assumptions are most likely to be approximately
true in the specific scientific context.
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A. APPENDIX 1
Here, we prove that if there is conditional effect homogeneity in distribution, then the
parameter β2 must be equal to zero in the regression model
logit Pr(Y = 1|A,P, V ) = β0 + β1A+ β2P + β4V (1)
To do so, we will make the following assumptions:
Y a ⊥ P |V ∀a(∵ Conditional effect homogeneity in distribution)
Y a ⊥ A|V, P = s ∀a(∵ Conditionalexchangeabilityinstudypopulation)
Y a = Y if A = a(∵ Consistency)
By consistency and exchangeability, the model can be rewritten as a structural model:
logit Pr(Y a = 1|P, V ) = β0 + β1a + β2P + β4V (2)
If P = 0, we have:
logit Pr(Y a = 1|P = 0, V ) = β0 + β1a + β4V (3)
If P = 1, we have:
logit Pr(Y a = 1|P = 1, V ) = β0 + β1a+ β2 + β4V (4)
By the assumption of effect homogeneity in distribution, we can set these equal:
β0 + β1a+ β4V = β0 + β1a+ β2 + β4V
Solving this for β2 we get β2 = 0
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B. APPENDIX 2
Proofs of identifying expressions from table 2. We note that these expressions have all
been proved elsewhere, and are included here only for completeness:
B.1 Approach 1
∑
v
[
RRs,v × Pr(V = v|Y
a=0 = 1, P = t)
]
=
∑
v
[
RRt,v × Pr(V = v|Y
a=0 = 1, P = t)
]
(∵ RRs,v = RRt,v)
=
∑
v
[
Pr(Y a=1 = 1|V = v, P = t)× Pr(V = v|Y a=0 = 1, P = t)
Pr(Y a=0 = 1|V = v, P = t)
]
=
∑
v
[
Pr(Y a=1 = 1|V = v, P = t)× Pr(Y a=0 = 1|V = v, P = t)× Pr(V = v|P = t)
Pr(Y a=0 = 1|V = v, P = t)× Pr(Y a=0 = 1|P = t)
]
=
∑
v
[
Pr(Y a=1 = 1|V = v, P = t)× Pr(V = v|P = t)
Pr(Y a=0 = 1|P = t)
]
=
∑
v [Pr(Y
a=1 = 1|V = v, P = t)× Pr(V = v|P = t)]
Pr(Y a=0 = 1|P = t)
=
Pr(Y a=1 = 1|P = t)
Pr(Y a=0 = 1|P = t)
= RRt
(5)
B.2 Approach 2
∑
v
[
Pr(Y a=0 = 1|V = v, P = t)× RRs,v × Pr(V = v|P = t)
]
=
∑
v
[
Pr(Y a=0 = 1|V = v, P = t)× RRt,v × Pr(V = v|P = t)
]
(∵ RRs,v = RRt,v)
=
∑
v
[
Pr(Y a=0 = 1|V = v, P = t)×
Pr(Y a=1 = 1|V = v, P = t)
Pr(Y a=0 = 1|V = v, P = t)
× Pr(V = v|P = t)
]
=
∑
v
[
Pr(Y a=1 = 1|V = v, P = t)× Pr(V = v|P = t)
]
= Pr(Y a=1 = 1|P = t)
(6)
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B.3 Approach 3∑
v
[Pr(Y a = 1|V = v, P = s)× Pr(V = v|P = t)]
=
∑
v
[Pr(Y a = 1|V = v, P = t)× Pr(V = v|P = t)] (∵ Y a ⊥ P |V ∀a)
= Pr(Y a = 1|P = t)
(7)
B.4 Approach 4
We are here assuming that Y is a binary variable, the proof generalizes readily to settings
with continuous or time-to-event outcomes. In order to simplify the logic, we will further
assume that the same set of baseline covariates V is sufficient to control both for con-
founding for A, and for differences between populations. In other words, we will assume
conditional exchangeability in the study population (Y a ⊥ A|V = v, P = s ∀a) and
conditional effect homogeneity in distribution (Y a ⊥ P |V = v ∀a). Before we begin, it is
useful to note that Pr(A=a,V =v,P =s)
Pr(A=a|P =s,V =v)×Pr(P =s|V =v)
= Pr(V = v). This follows from sequential
application of the definition of conditional probability.
E
[
Y × I(A = a, P = s)
Pr(A = a|V = vi, P = s)× Pr(P = s|V = vi)
]
=
∑
v
[
Pr(Y = 1|A = a, V = v, P = s)× Pr(A = a, V = v, P = s)
Pr(A = a|P = s, V = v)× Pr(P = s|V = v)
]
(Rewriting at group level)
=
∑
v
[Pr(Y = 1|A = a, V = v, P = s)× Pr(V = v)]
=
∑
v
[Pr(Y a = 1|A = a, V = v, P = s)× Pr(V = v)] (∵ Consistency)
=
∑
v
[Pr(Y a = 1|V = v, P = s)× Pr(V = v)] (∵ Y a ⊥ A|V, P = s ∀a)
=
∑
v
[Pr(Y a = 1|V = v)× Pr(V = v)] (∵ Y a ⊥ P |V ∀a)
= Pr(Y a = 1)
(8)
B.5 Approach 5
The proof of approach 5 is closely related to that for approach 4. Westreich et al[27]
provide a full proof in the appendix.
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